• Pharmacology
  • Allergy, Immunology, and ENT
  • Cardiology
  • Emergency Medicine
  • Endocrinology
  • Adolescent Medicine
  • Gastroenterology
  • Infectious Diseases
  • Neurology
  • OB/GYN
  • Practice Improvement
  • Gynecology
  • Respiratory
  • Dermatology
  • Mental, Behavioral and Development Health
  • Oncology
  • Rheumatology
  • Sexual Health
  • Pain

FDA approves dupilumab for atopic dermatitis treatment in pediatrics

Article

The US Food and Drug Administration has approved dupilumab (Dupixent, Sanofi and Regeneron) for the treatment of moderate-to-severe atopic dermatitis in children aged 6 to 11 years.

The US Food and Drug Administration has approved dupilumab (Dupixent, Sanofi and Regeneron) for the treatment of moderate-to-severe atopic dermatitis in children aged 6 to 11 years. According to Sanofi, dupilumab is the only biologic approved for this patient population following the approval.

The approval was based on the results of a phase 3 clinical study. The results of the study showed that children who were treated with dupilumab and topical corticosteroids had significant improvement in overall disease severity, skin clearance, and itch.

For more on the approval, check out our sister publication Drug Topics.

Related Videos
Lawrence Eichenfield, MD
Lawrence Eichenfield, MD | Image credit: KOL provided
FDA approves B-VEC to treat dystrophic epidermolysis bullosa patients 6 months and older | Image Credit: bankrx - Image Credit: bankrx - stock.adobe.com.
Related Content
© 2024 MJH Life Sciences

All rights reserved.